News | Atrial Fibrillation | May 19, 2020

Atrial Fibrosis Predicts Recurrent Stroke or New AF Onset 

HRS late-breaking study found predictors in patients with embolic stroke of undetermined source

Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,

May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking study at the Heart Rhythm Society (HRS) 2020 Science virtual meeting hypothesized ESUS patients with advanced atrial disease are at higher risk for recurrent stroke or incident atrial fibrillation (AF).

The study found ESUS patients with fibrosis, about 12 percent, had a significantly higher proportion of the combined outcome of recurrent stroke or new AF compared to those with fibrosis , less than 12 percent (5 vs. 22.6%; p=0.045).

Patients with ESUS have atrial fibrosis comparable to that seen in AF. Atrial fibrosis in about 12% may help identify ESUS patients who may benefit from anticoagulation for secondary prevention, said Nazem Akoum, M.D., MS, FHRS, attending physician, University of Washington Medical Center, Heart Institute of Edmonds, Seattle. He presented the study "Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study," at HRS. 

Researchers quantified atrial fibrosis using late-gadolinium enhancement MRI. Atrial fibrosis was reported as a percentage of the left atrial wall volume and compared across various groups: healthy controls, lacunar stroke, ESUS and known AF with or without prior stroke. They followed ESUS patients prospectively for 30 months for recurrent ischemic stroke or new AF.

The study enrolled 201 patients, 101 without AF: 35 healthy controls, 15 lacunar strokes, 51 patients with ESUS; and 100 patients with AF: 50 with prior stroke and 50 without prior stroke. Atrial fibrosis was significantly higher in ESUS compared to lacunar stroke patients (14.69±6.39% vs. 10.76±8.30; p = 0.02) and to healthy controls (8.1±7.9%; <0.0001). ESUS patients had comparable fibrosis to patients with AF with (17.9±11.4%) or without prior stroke (16.6±9.2%; p=NS for both) (Figure 1). In prospective follow up of ESUS, 5 patients (9.8%) had recurrent stroke and 5 had incident AF (9.8%). 

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Related Content

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat
The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr